Exploring the links between cancer and placenta development.

Vincenzo Costanzo , Alberto Bardelli , Salvatore Siena , Sergio Abrignani
Open Biology 8 ( 6) 180081 -180091

100
2018
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model

Patricia Alamo , Alberto Gallardo , Federica Di Nicolantonio , Miguel Angel Pavón
The FASEB Journal 29 ( 2) 464 -476

33
2015
Mutational analysis of gene families in human cancer

Alberto Bardelli , Victor E Velculescu
Current Opinion in Genetics & Development 15 ( 1) 5 -12

48
2005
Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET -mediated metastasis

Alberto Bardelli , Maria Lisa Basile , Enrica Audero , Silvia Giordano
Oncogene 18 ( 5) 1139 -1146

83
1999
Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET.

Elisa Vigna , Daniela Gramaglia , Paola Longati , Alberto Bardelli
Oncogene 18 ( 29) 4275 -4281

53
1999
Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists.

Paolo Michieli , Cristina Basilico , Selma Pennacchietti , Antonella Maffè
Oncogene 18 ( 37) 5221 -5231

126
1999
Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2

Daniel Besser , Alberto Bardelli , Svetlana Didichenko , Marcus Thelen
Oncogene 14 ( 6) 705 -711

42
1997
Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential.

Alberto Bardelli , Paola Longati , Daniela Gramaglia , Maria C Stella
Oncogene 15 ( 25) 3103 -3111

133
1997
Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know.

Marco Calandri , Giulia Siravegna , Steven M. Yevich , Giuseppe Stranieri
European Radiology 30 ( 8) 4496 -4503

2
2020
Tracking the genomic evolution of breast cancer metastasis

Davide Zecchin , Alberto Bardelli
Breast Cancer Research 12 ( 1) 302 -302

1
2010
PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

Cornelia Liedtke , Luca Cardone , Attila Tordai , Kai Yan
Breast Cancer Research 10 ( 2) 1 -10

50
2008
Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer.

Alessio Amatu , Silvio Veronese , Calogero Lauricella , Erica Bonazzina
ESMO open 1 ( 4)

4
2016
Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases

Giulia Siravegna , Elena Geuna , Benedetta Mussolin , Giovanni Crisafulli
ESMO Open 2 ( 4)

34
2017
Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients

Giovanni Crisafulli , Benedetta Mussolin , Andrea Cassingena , Monica Montone
ESMO Open 4 ( 6)

3
2019
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial.

Andrea Sartore-Bianchi , Sara Lonardi , Cosimo Martino , Elisabetta Fenocchio
ESMO open 5 ( 5) 1 -8

65
2020
Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions.

Gabriele Picco , Consalvo Petti , Alessia Centonze , Erica Torchiaro
Embo Molecular Medicine 9 ( 3) 293 -303

51
2017
Understanding how kinase-targeted therapies work

Sabrina Arena , Alberto Bardelli
Cell Cycle 7 ( 11) 1560 -1563

2
2008
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets

Enzo Medico , Mariangela Russo , Gabriele Picco , Carlotta Cancelliere
Nature Communications 6 ( 1) 7002

251
2015
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers

Sandra Misale , Ivana Bozic , Jingshan Tong , Ashley Peraza-Penton
Nature Communications 6 ( 1) 8305 -8305

77
2015